Nextcure Inc (NXTC)

$1.98 -0.10 (-4.58%)
Market Cap 7.50M
Revenue (ttm) 0.00
Net Income (ttm) -55.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 141,500
Avg Vol 91,902
Day's Range N/A - N/A
Shares Out 3.61M
Stochastic %K 5%
Beta 1.30
Analysts Strong Sell
Price Target $17.67

Company Profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease;...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 399 4900
Address:
9000 Virginia Manor Road, Suite 200, Beltsville, United States
teatone
teatone Jun. 15 at 11:57 AM
$NXTC go green
0 · Reply
MSG8898
MSG8898 Jun. 12 at 8:50 PM
$NXTC lol, was trading at 3x multiple weeks ago. Print print print!!!!!!
0 · Reply
MGAP
MGAP Jun. 11 at 1:28 PM
$NXTC shhhhh
0 · Reply
MSG8898
MSG8898 Jun. 10 at 8:31 PM
$NXTC how many shares printed today? Print print print!!!!! Lol, a P1 pipeline stock that has almost a quarterly loss of a p3 stock. Come on!
0 · Reply
Fakhrul123
Fakhrul123 Jun. 10 at 11:11 AM
$NXTC $10
0 · Reply
MSG8898
MSG8898 Jun. 9 at 8:51 PM
$NXTC IMO it's overwhelming clear that they used the P1 good news to print tons of shares via the ATM. Othernot you tell me another way to support this huge quarterly spending based on the early stage pipeline.
0 · Reply
Zackpedia
Zackpedia Jun. 9 at 7:46 PM
$NXTC 2.36 now nice!
0 · Reply
Zackpedia
Zackpedia Jun. 9 at 7:38 PM
$NXTC Support at 2.4
0 · Reply
Zackpedia
Zackpedia Jun. 5 at 4:05 PM
$NXTC Down to 2.8 support, you could’ve…
0 · Reply
Rusty_Shackelford2024
Rusty_Shackelford2024 Jun. 5 at 12:44 PM
$NXTC how did this get good phase one data and drop 3 bucks a share. Preposterous
0 · Reply
Latest News on NXTC
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers

Jun 4, 2026, 8:00 AM EDT - 12 days ago

NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers

NextCure Transcript: KOL event

Jun 2, 2026, 8:00 AM EDT - 14 days ago

NextCure Transcript: KOL event

NextCure Press release: KOL event

Jun 2, 2026, 8:00 AM EDT - 14 days ago

NextCure Press release: KOL event

NextCure Slides: KOL event

Jun 2, 2026, 8:00 AM EDT - 14 days ago

NextCure Slides: KOL event

NextCure share weakness overdone, says Lucid Capital

2026-06-02T10:10:04.000Z - 14 days ago

NextCure share weakness overdone, says Lucid Capital

NextCure presents Phase 1 data for SIM0505 in gynecologic cancers

2026-06-01T13:49:45.000Z - 14 days ago

NextCure presents Phase 1 data for SIM0505 in gynecologic cancers

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

Jun 1, 2026, 8:00 AM EDT - 15 days ago

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

NextCure initiated with a Buy at Lucid Capital

2026-05-11T12:05:03.000Z - 5 weeks ago

NextCure initiated with a Buy at Lucid Capital

NextCure reports Q1 EPS ($1.87), consensus ($2.03)

2026-05-07T22:46:09.000Z - 5 weeks ago

NextCure reports Q1 EPS ($1.87), consensus ($2.03)

NextCure Provides Business Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 4:05 PM EDT - 5 weeks ago

NextCure Provides Business Update and Reports First Quarter 2026 Financial Results

NextCure Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 5 weeks ago

NextCure Quarterly report: Q1 2026

NextCure Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 5 weeks ago

NextCure Earnings release: Q1 2026

NextCure Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 5 weeks ago

NextCure Slides: Corporate presentation

NextCure initiates dose optimization portion of SIM0505 study

2026-05-04T12:10:48.000Z - 6 weeks ago

NextCure initiates dose optimization portion of SIM0505 study

NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers

May 4, 2026, 7:05 AM EDT - 6 weeks ago

NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers

NextCure Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 7 weeks ago

NextCure Proxy statement: Proxy filing

NextCure Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 7 weeks ago

NextCure Proxy statement: Proxy filing

NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026

Apr 21, 2026, 10:15 AM EDT - 7 weeks ago

NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026

NextCure granted Fast Track Designation for SIM0505 by FDA

2026-04-07T14:31:45.000Z - 2 months ago

NextCure granted Fast Track Designation for SIM0505 by FDA

NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer

Apr 7, 2026, 8:05 AM EDT - 2 months ago

NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer

NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026

Mar 31, 2026, 4:05 PM EDT - 2 months ago

NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026

NextCure Provides Business Update and Reports Full Year 2025 Financial Results

Mar 5, 2026, 4:05 PM EST - 3 months ago

NextCure Provides Business Update and Reports Full Year 2025 Financial Results

NextCure Annual report: Q4 2025

Mar 5, 2026, 4:00 PM EST - 3 months ago

NextCure Annual report: Q4 2025

NextCure Earnings release: Q4 2025

Mar 5, 2026, 4:00 PM EST - 3 months ago

NextCure Earnings release: Q4 2025

NextCure trading resumes

2026-03-02T14:55:36.000Z - 3 months ago

NextCure trading resumes

NextCure trading halted, volatility trading pause

2026-03-02T14:45:08.000Z - 3 months ago

NextCure trading halted, volatility trading pause

NextCure expects SIM0505 Phase 1 dose escalation data update in Q2

2026-01-23T12:05:31.000Z - 5 months ago

NextCure expects SIM0505 Phase 1 dose escalation data update in Q2

NextCure Provides Business Update

Jan 23, 2026, 7:00 AM EST - 5 months ago

NextCure Provides Business Update

NextCure Slides: Corporate presentation

Jan 21, 2026, 7:00 AM EST - 5 months ago

NextCure Slides: Corporate presentation

NextCure Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 11:00 AM EST - 6 months ago

NextCure Transcript: Piper Sandler 37th Annual Healthcare Conference

NextCure files to sell 2.52M shares of common stock for holders

2025-11-26T21:05:41.000Z - 7 months ago

NextCure files to sell 2.52M shares of common stock for holders

NextCure Registration statement: Registration Filing

Nov 26, 2025, 7:00 AM EST - 7 months ago

NextCure Registration statement: Registration Filing

NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 8:00 AM EST - 7 months ago

NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference

NextCure announces closing of $21.5M PIPE financing

2025-11-17T13:16:03.000Z - 7 months ago

NextCure announces closing of $21.5M PIPE financing

NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts

Nov 17, 2025, 8:00 AM EST - 7 months ago

NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts

NextCure prices 2.5M shares at $8.52 in private placement

2025-11-12T13:25:47.000Z - 7 months ago

NextCure prices 2.5M shares at $8.52 in private placement

NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

Nov 12, 2025, 8:00 AM EST - 7 months ago

NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

NextCure upgraded to Buy from Neutral at Ladenburg

2025-11-07T12:25:44.000Z - 7 months ago

NextCure upgraded to Buy from Neutral at Ladenburg

NextCure reports Q3 EPS ($3.22), consensus ($3.98)

2025-11-05T22:01:30.000Z - 7 months ago

NextCure reports Q3 EPS ($3.22), consensus ($3.98)

NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 7 months ago

NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results

NextCure Quarterly report: Q3 2025

Nov 5, 2025, 4:00 PM EST - 7 months ago

NextCure Quarterly report: Q3 2025

NextCure Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 7 months ago

NextCure Earnings release: Q3 2025

NextCure, Simcere Zaiming announce expansion of Phase 1 trial of SIM0505

2025-10-16T12:20:47.000Z - 8 months ago

NextCure, Simcere Zaiming announce expansion of Phase 1 trial of SIM0505

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

Oct 16, 2025, 8:05 AM EDT - 8 months ago

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

NextCure Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 4:00 PM EDT - 10 months ago

NextCure Transcript: H.C. Wainwright 27th Annual Global Investment Conference

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:00 AM EDT - 10 months ago

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 11 months ago

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

NextCure Quarterly report: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 11 months ago

NextCure Quarterly report: Q2 2025

NextCure Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 11 months ago

NextCure Earnings release: Q2 2025

NextCure presents new preclinical data on osteogenesis imperfecta treatment

2025-07-24T22:10:16.000Z - 11 months ago

NextCure presents new preclinical data on osteogenesis imperfecta treatment

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Jul 24, 2025, 4:05 PM EDT - 11 months ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NextCure files to sell 339,000 shares of common stock for holders

2025-07-19T02:20:32.000Z - 11 months ago

NextCure files to sell 339,000 shares of common stock for holders

NextCure Registration statement: Registration Filing

Jul 18, 2025, 8:00 AM EDT - 11 months ago

NextCure Registration statement: Registration Filing

NextCure price target lowered to $15 from $36 at Piper Sandler

2025-07-15T10:51:25.000Z - 1 year ago

NextCure price target lowered to $15 from $36 at Piper Sandler

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

Jun 16, 2025, 10:03 AM EDT - 1 year ago

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

Jun 16, 2025, 7:05 AM EDT - 1 year ago

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

May 29, 2025, 4:05 PM EDT - 1 year ago

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

NextCure Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

NextCure Proxy statement: Proxy Filing

NextCure Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

NextCure Proxy statement: Proxy Filing

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

May 1, 2025, 4:05 PM EDT - 1 year ago

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

NextCure Quarterly report: Q1 2025

May 1, 2025, 4:00 PM EDT - 1 year ago

NextCure Quarterly report: Q1 2025

NextCure Earnings release: Q1 2025

May 1, 2025, 4:00 PM EDT - 1 year ago

NextCure Earnings release: Q1 2025

NextCure Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

NextCure Proxy statement: Proxy Filing

NextCure Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

NextCure Proxy statement: Proxy Filing

NextCure Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

NextCure Proxy statement: Proxy Filing

NextCure Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 10, 2025, 8:45 AM EDT - 1 year ago

NextCure Transcript: 24th Annual Needham Virtual Healthcare Conference

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

Apr 4, 2025, 7:00 AM EDT - 1 year ago

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

Mar 6, 2025, 4:05 PM EST - 1 year ago

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

NextCure Earnings release: Q4 2024

Mar 6, 2025, 4:00 PM EST - 1 year ago

NextCure Earnings release: Q4 2024

NextCure Annual report: Q4 2024

Mar 6, 2025, 4:00 PM EST - 1 year ago

NextCure Annual report: Q4 2024

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

Jan 10, 2025, 8:05 AM EST - 1 year ago

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

NextCure Announces Acceptance of IND Application for LNCB74

Dec 10, 2024, 8:05 AM EST - 1 year ago

NextCure Announces Acceptance of IND Application for LNCB74

NextCure Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 5, 2024, 12:00 PM EST - 1 year ago

NextCure Transcript: Piper Sandler 36th Annual Healthcare Conference

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Nov 19, 2024, 8:05 AM EST - 1 year ago

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 4:05 PM EST - 1 year ago

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

NextCure Earnings release: Q3 2024

Nov 7, 2024, 3:00 PM EST - 1 year ago

NextCure Earnings release: Q3 2024

NextCure Quarterly report: Q3 2024

Nov 7, 2024, 3:00 PM EST - 1 year ago

NextCure Quarterly report: Q3 2024

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

Nov 5, 2024, 4:05 PM EST - 1 year ago

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 1 year ago

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

Sep 16, 2024, 8:05 AM EDT - 1 year ago

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

NextCure Quarterly report: Q2 2024

Aug 1, 2024, 4:00 PM EDT - 2 years ago

NextCure Quarterly report: Q2 2024

NextCure Earnings release: Q2 2024

Aug 1, 2024, 4:00 PM EDT - 2 years ago

NextCure Earnings release: Q2 2024

NextCure Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 27, 2024, 7:00 AM EDT - 2 years ago

NextCure Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 20, 2024, 4:10 PM EDT - 2 years ago

NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

May 30, 2024, 4:05 PM EDT - 2 years ago

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

May 2, 2024, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

NextCure Quarterly report: Q1 2024

May 2, 2024, 4:00 PM EDT - 2 years ago

NextCure Quarterly report: Q1 2024

NextCure Earnings release: Q1 2024

May 2, 2024, 4:00 PM EDT - 2 years ago

NextCure Earnings release: Q1 2024

NextCure Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

NextCure Proxy statement: Proxy Filing

NextCure Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

NextCure Proxy statement: Proxy Filing

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

Apr 24, 2024, 4:05 PM EDT - 2 years ago

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

NextCure Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

NextCure Proxy statement: Proxy Filing

NextCure Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 11, 2024, 12:45 PM EDT - 2 years ago

NextCure Transcript: 23rd Annual Needham Virtual Healthcare Conference

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Apr 8, 2024, 7:00 AM EDT - 2 years ago

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

Apr 4, 2024, 7:05 AM EDT - 2 years ago

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 7:00 AM EDT - 2 years ago

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Mar 21, 2024, 8:55 AM EDT - 2 years ago

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

NextCure Earnings release: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

NextCure Earnings release: Q4 2023

NextCure Annual report: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

NextCure Annual report: Q4 2023

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

Mar 5, 2024, 8:05 AM EST - 2 years ago

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Jan 18, 2024, 4:05 PM EST - 2 years ago

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Dec 21, 2023, 7:05 AM EST - 2 years ago

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

NextCure Provides Year-End Clinical Pipeline Updates

Dec 14, 2023, 6:45 AM EST - 2 years ago

NextCure Provides Year-End Clinical Pipeline Updates

NextCure Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 30, 2023, 1:30 PM EST - 2 years ago

NextCure Transcript: Piper Sandler 35th Annual Healthcare Conference

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 7:00 AM EST - 2 years ago

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

Nov 15, 2023, 4:05 PM EST - 2 years ago

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

NextCure Quarterly report: Q3 2023

Nov 2, 2023, 5:00 PM EDT - 2 years ago

NextCure Quarterly report: Q3 2023

NextCure Earnings release: Q3 2023

Nov 2, 2023, 5:00 PM EDT - 2 years ago

NextCure Earnings release: Q3 2023

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Nov 2, 2023, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

Oct 17, 2023, 8:05 AM EDT - 2 years ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Disease

Sep 26, 2023, 4:05 PM EDT - 2 years ago

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Disease

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

Sep 12, 2023, 8:05 AM EDT - 3 years ago

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen

Sep 7, 2023, 4:05 PM EDT - 3 years ago

NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen

teatone
teatone Jun. 15 at 11:57 AM
$NXTC go green
0 · Reply
MSG8898
MSG8898 Jun. 12 at 8:50 PM
$NXTC lol, was trading at 3x multiple weeks ago. Print print print!!!!!!
0 · Reply
MGAP
MGAP Jun. 11 at 1:28 PM
$NXTC shhhhh
0 · Reply
MSG8898
MSG8898 Jun. 10 at 8:31 PM
$NXTC how many shares printed today? Print print print!!!!! Lol, a P1 pipeline stock that has almost a quarterly loss of a p3 stock. Come on!
0 · Reply
Fakhrul123
Fakhrul123 Jun. 10 at 11:11 AM
$NXTC $10
0 · Reply
MSG8898
MSG8898 Jun. 9 at 8:51 PM
$NXTC IMO it's overwhelming clear that they used the P1 good news to print tons of shares via the ATM. Othernot you tell me another way to support this huge quarterly spending based on the early stage pipeline.
0 · Reply
Zackpedia
Zackpedia Jun. 9 at 7:46 PM
$NXTC 2.36 now nice!
0 · Reply
Zackpedia
Zackpedia Jun. 9 at 7:38 PM
$NXTC Support at 2.4
0 · Reply
Zackpedia
Zackpedia Jun. 5 at 4:05 PM
$NXTC Down to 2.8 support, you could’ve…
0 · Reply
Rusty_Shackelford2024
Rusty_Shackelford2024 Jun. 5 at 12:44 PM
$NXTC how did this get good phase one data and drop 3 bucks a share. Preposterous
0 · Reply
Fakhrul123
Fakhrul123 Jun. 5 at 10:59 AM
$NXTC
0 · Reply
Zackpedia
Zackpedia Jun. 3 at 10:49 AM
$NXTC Down to 3.2 pre
1 · Reply
Zackpedia
Zackpedia Jun. 2 at 2:03 PM
$NXTC Down to 3.3 niw! You could’ve sold…
0 · Reply
Zackpedia
Zackpedia Jun. 2 at 11:51 AM
$NXTC Selling time at 3.7 now!
0 · Reply
Zackpedia
Zackpedia Jun. 2 at 9:20 AM
$NXTC You could’ve sold at 3.54 when I alerted and bought back at 3.3 now if you wanted.
0 · Reply
Zackpedia
Zackpedia Jun. 2 at 9:05 AM
$NXTC Resistance at 3.74
0 · Reply
Zackpedia
Zackpedia Jun. 2 at 7:48 AM
$NXTC Support at 3
0 · Reply
Fakhrul123
Fakhrul123 Jun. 2 at 7:35 AM
$NXTC result came out good! But why the panic sell!!!
0 · Reply
Merlintrader
Merlintrader Jun. 2 at 2:48 AM
$IDYA ASCO 2026 Oncology Signals: $IDYA, $IMRX and $NXTC Put Three Very Different Cancer Stories in Focus https://www.merlintrader.com/asco-2026-oncology-signals-idya-imrx-nxtc/
0 · Reply
MSG8898
MSG8898 Jun. 2 at 1:58 AM
$NXTC is this a turd?
0 · Reply
PB09
PB09 Jun. 1 at 7:07 PM
$NXTC Took a swing trade here at $3
0 · Reply
Rusty_Shackelford2024
Rusty_Shackelford2024 Jun. 1 at 4:13 PM
$NXTC who has been here for a while? Seems like no news? Strange price action.
0 · Reply